UY38720A - Métodos para tratar cánceres asociados con virus con inhibidores de la histona deacetilasa - Google Patents

Métodos para tratar cánceres asociados con virus con inhibidores de la histona deacetilasa

Info

Publication number
UY38720A
UY38720A UY0001038720A UY38720A UY38720A UY 38720 A UY38720 A UY 38720A UY 0001038720 A UY0001038720 A UY 0001038720A UY 38720 A UY38720 A UY 38720A UY 38720 A UY38720 A UY 38720A
Authority
UY
Uruguay
Prior art keywords
inhibitors
methods
associated cancers
treating virus
histone
Prior art date
Application number
UY0001038720A
Other languages
English (en)
Inventor
Robert Mcrae
L Brown Gail
David Slack
Smith WARREN Marshelle
Richard Trauger
Xiaohu Deng
Original Assignee
Viracta Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Viracta Therapeutics Inc filed Critical Viracta Therapeutics Inc
Publication of UY38720A publication Critical patent/UY38720A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4406—Non condensed pyridines; Hydrogenated derivatives thereof only substituted in position 3, e.g. zimeldine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pain & Pain Management (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

En el presente documento se describen ciertos montos y calendarios de dosificación que evitan y gestionan de manera eficaz los efectos colaterales asociados con el tratamiento con inhibidores de la histona deacetilasa. Opcionalmente, estos calendarios y regímenes de dosificación incluyen tratamiento con un agente antiviral.
UY0001038720A 2019-05-31 2020-05-28 Métodos para tratar cánceres asociados con virus con inhibidores de la histona deacetilasa UY38720A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201962855454P 2019-05-31 2019-05-31

Publications (1)

Publication Number Publication Date
UY38720A true UY38720A (es) 2020-12-31

Family

ID=73552282

Family Applications (1)

Application Number Title Priority Date Filing Date
UY0001038720A UY38720A (es) 2019-05-31 2020-05-28 Métodos para tratar cánceres asociados con virus con inhibidores de la histona deacetilasa

Country Status (4)

Country Link
AR (1) AR119033A1 (es)
CL (1) CL2021003170A1 (es)
UY (1) UY38720A (es)
WO (1) WO2020243326A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202134232A (zh) 2019-12-05 2021-09-16 美商維拉克塔治療公司 Hdac抑制劑固態形式
IL302289A (en) 2020-10-28 2023-06-01 Viracta Subsidiary Inc Solid state forms of HDAC inhibitor
WO2024086688A1 (en) * 2022-10-21 2024-04-25 Viracta Subsidiary, Inc. Dosing methods for hdac inhibitor compounds

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016014484A1 (en) * 2014-07-21 2016-01-28 The Rockefeller University Combination of broadly neutralizing hiv antibodies and viral inducers
US20180185345A1 (en) * 2015-06-19 2018-07-05 Trustees Of Boston University Methods and compositions for treating herpesvirus induced conditions

Also Published As

Publication number Publication date
TW202110452A (zh) 2021-03-16
AR119033A1 (es) 2021-11-17
CL2021003170A1 (es) 2022-07-15
WO2020243326A1 (en) 2020-12-03

Similar Documents

Publication Publication Date Title
UY38720A (es) Métodos para tratar cánceres asociados con virus con inhibidores de la histona deacetilasa
CL2021000084A1 (es) Inhibidores de pd-1/pd-l1
CY1123678T1 (el) Χρηση αναστολεων μυοστατινης και θεραπειες συνδυασμου
CO2019013010A2 (es) Inhibidores de kras g12c y métodos para su uso
CO2020009861A2 (es) Inhibidores pd-1/pd-l1
CL2017002494A1 (es) Inhibidores de indolamina-2, 3- dioxigenasa para el tratamiento de cancer
CO2017013234A2 (es) Mezcla para tratar fertilizantes que contienen urea
DOP2017000268A (es) Metodos y kits para tratar depresion
BR112017000301A2 (pt) tratamento de leucemia com inibidores de histona desacetilase
MX2020003959A (es) Metodos terapeuticos relacionados con los inhibidores de hsp90.
BR112018009311A2 (pt) ?método para tratar um sujeito humano sofrendo de tma persistente associada com transplante de célula tronco hematopoiética?
MX2020004837A (es) Inhibidores de la vía de adenosina para el tratamiento del cáncer.
CR20170259A (es) Terapias de envenenamiento y composiciones farmacéuticas, sistemas y equipos relacionados
EA202191557A1 (ru) Комбинированная терапия радиоиммуноконъюгатами и ингибиторами репарации повреждений днк
BR112018008882A2 (pt) método para tratar um distúrbio proliferativo e produto farmacêutico
CL2017002765A1 (es) El uso de estimuladores sgc, activadores gc, solos y combinaciones con inhibidores pde5 para el tratamiento de úlceras digitales (du) concomitante con esclerosis sistémica (ssc).
MX2021006326A (es) Inhibidores de pcna.
MX2020004179A (es) Combinacion que comprende al menos un modulador de espliceosomas y al menos un inhibidor elegido de inhibidores de bcl2, bcl2/bclxl y bclxl, y metodos de uso.
UY38352A (es) Inhibidores de integrina alfavbeta6
CL2016002151A1 (es) Derivados de piridazina para uso en la prevención o el tratamiento de un trastorno atáxico
CO2024009571A2 (es) Inhibidores de parp1
UY37800A (es) AGENTES DE iARN PARA LA INHIBICIÓN DE LA EXPRESIÓN DE ALFA-ENaC Y MÉTODOS DE USO
ZA202103975B (en) Methods of treating disease with magl inhibitors
PE20210109A1 (es) Moduladores de la expresion de irf4
CL2021001246A1 (es) Moduladores de expresión irf5.